Olema Pharmaceuticals/$OLMA
1D1W1MYTD1Y5YMAX
Capital at risk
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
- Ticker
- $OLMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 150
- Headquarters
- San Francisco, United States
- Website
- olema.com
OLMA Metrics
BasicAdvanced
$866M
-
-$2.13
2.01
-
Price and volume
Market cap
$866M
Beta
2.01
52-week high
$36.26
52-week low
$6.65
Average daily volume
1M
Financial strength
Current ratio
8.863
Quick ratio
8.757
Long term debt to equity
0.007
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-220.675
Management effectiveness
Return on assets (TTM)
-31.82%
Return on equity (TTM)
-52.74%
Valuation
Price to book
2.01
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
-5.767
Free cash flow yield (TTM)
-17.34%
Free cash flow per share (TTM)
-1.717
Growth
Earnings per share change (TTM)
9.98%
3-year earnings per share growth (CAGR)
-4.11%
What the Analysts think about OLMA
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
Analyst projections of the future price of Olema Pharmaceuticals stock.
Bulls say / Bears say
The company ended Q1 2026 with $505.3 million in cash, cash equivalents, and marketable securities, providing a runway into late 2027 at current burn rates (Reuters)
Olema secured its first clinical collaboration by partnering with Bayer to evaluate OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer, expanding its oncology portfolio and potential addressable market (Reuters)
Q1 net loss widened to $53.1 million from $30.4 million a year ago, driven by higher late-stage palazestrant and early-stage OP-3136 development costs, signaling accelerating cash burn that could pressure resources (Reuters)
Enrollment in the pivotal Phase 3 OPERA-01 trial completed, but the top-line palazestrant readout was delayed to Q1 2027, deferring a key de-risking catalyst by at least one quarter (GlobeNewswire)
OP-3136 remains in Phase 1 with only preliminary data from a small cohort, leaving substantial uncertainty around dose optimization, longer-term safety, and efficacy in later-stage trials (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
OLMA Financial Performance
Revenues and expenses
OLMA Earnings Performance
Company profitability
Upcoming events
No upcoming events
OLMA News
AllArticlesVideos
Funds containing OLMA
AllUSDGBPEUR
Fund name | Fund size | $OLMA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.